Cambridge Cognition Reports First Patient Dosed in Monument Therapeutics Psychosis Risk Trial

Cambridge Cognition Holdings ( (GB:COG) ) just unveiled an announcement.

Cambridge Cognition reported that Monument Therapeutics, in which it holds a 20% stake, has dosed the first patient in a clinical trial of MT1988 for individuals at clinical high risk of psychosis. The study, run with the Foundation for the National Institutes of Health under the Accelerating Medicines Partnership Schizophrenia program, aims to address a population with no approved pharmacological treatments.

The randomised, placebo-controlled proof-of-principle trial will enrol 150 participants over eight weeks to evaluate MT1988’s impact on cognitive symptoms using clinical and cognitive biomarkers. Cambridge Cognition’s proprietary digital assessments underpinned MT1988’s early development and biomarker strategy, highlighting the company’s role in biomarker-driven neuroscience drug development and creating a potential value inflection for its associate Monument.

The most recent analyst rating on (GB:COG) stock is a Hold with a £36.00 price target. To see the full list of analyst forecasts on Cambridge Cognition Holdings stock, see the GB:COG Stock Forecast page.

Spark’s Take on GB:COG Stock

According to Spark, TipRanks’ AI Analyst, GB:COG is a Neutral.

Overall score reflects weak financial performance driven by declining revenue, ongoing losses, and negative operating/free cash flow, partially offset by improved equity on the balance sheet. Technicals are mixed (short-term strength but longer-term downtrend and overbought RSI), while valuation is constrained by loss-making results and no stated dividend yield.

To see Spark’s full report on GB:COG stock, click here.

More about Cambridge Cognition Holdings

Cambridge Cognition is a UK-based neuroscience technology company specialising in digital cognitive assessments that support scientific discovery, accelerate drug development and improve patient care. Its touchscreen and voice-based tests, delivered under the CANTAB and Winterlight brands, target both consumer and clinical settings, with disease-specific modules for conditions including schizophrenia, Parkinson’s, ADHD, multiple sclerosis, depression and dementias.

Average Trading Volume: 30,915

Technical Sentiment Signal: Hold

Current Market Cap: £18.85M

See more data about COG stock on TipRanks’ Stock Analysis page.